The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...

The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim ...

Shares in the UK's IP Group slid today after it revealed that an arthritis drug in development at one of its portfolio ...

Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...

It is unclear why an independent data safety monitoring board recommended the suspension of Pliant’s Phase IIb/III BEACON-IPF ...

In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...

A clinical study testing a Pliant Therapeutics drug once considered a promising prospect for treating a fatal lung disorder is now on pause at the recommendation of independent outside observers.

Patients currently enrolled in BEACON-IPF will remain in the trial ... the risks inherent in the drug development process, ...

Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...